Pramlintide
Metabolic
ABOUT
Pramlintide is a synthetic amylin analogue approved as Symlin for use alongside mealtime insulin in type 1 and type 2 diabetes. It is the approved reference point for the amylin mechanism that cagrilintide is built on.
EVIDENCE OVERVIEW
Supported by controlled human trials
WHAT THIS MEANS
Established. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
A synthetic analogue of human amylin, the hormone co-secreted with insulin by pancreatic beta cells, with three proline substitutions that prevent the aggregation which makes native human amylin unusable as a drug. It slows gastric emptying, suppresses inappropriate postprandial glucagon secretion, and increases satiety - it does not stimulate insulin secretion.
PHARMACOKINETICS
Half-life about 48 minutes after subcutaneous injection, with bioavailability of 30-40%. Given before major meals. It must be injected separately from insulin and not mixed in the same syringe, because mixing alters the pharmacokinetics of both.
REVIEW
PUBLISHED PAIR RECORDS
with Liraglutide
Labelled caution: two agents that slow gastric emptyingPramlintide labelling states that it slows gastric emptying, that it is not recommended for patients taking other drugs that alter gastrointestinal motility, and that concomitant oral medicines whose effect depends on a threshold concentration should be taken at least 1 hour before or 2 hours after injection. Liraglutide carries its own labelled statement that it delays gastric emptying and may affect the absorption of concomitantly administered oral medicines. This is therefore not an inference from shared mechanism - each product's own labelling describes the effect the other also produces. Pramlintide additionally carries a boxed warning for severe hypoglycaemia when used with insulin, and GLP-1 labelling records increased hypoglycaemia risk in combination with insulin or an insulin secretagogue. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Exenatide
Labelled caution: two agents that slow gastric emptyingPramlintide labelling states that it slows gastric emptying, that it is not recommended for patients taking other drugs that alter gastrointestinal motility, and that concomitant oral medicines whose effect depends on a threshold concentration should be taken at least 1 hour before or 2 hours after injection. Exenatide carries its own labelled statement that it delays gastric emptying and may affect the absorption of concomitantly administered oral medicines. This is therefore not an inference from shared mechanism - each product's own labelling describes the effect the other also produces. Pramlintide additionally carries a boxed warning for severe hypoglycaemia when used with insulin, and GLP-1 labelling records increased hypoglycaemia risk in combination with insulin or an insulin secretagogue. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Dulaglutide
Labelled caution: two agents that slow gastric emptyingPramlintide labelling states that it slows gastric emptying, that it is not recommended for patients taking other drugs that alter gastrointestinal motility, and that concomitant oral medicines whose effect depends on a threshold concentration should be taken at least 1 hour before or 2 hours after injection. Dulaglutide carries its own labelled statement that it delays gastric emptying and may affect the absorption of concomitantly administered oral medicines. This is therefore not an inference from shared mechanism - each product's own labelling describes the effect the other also produces. Pramlintide additionally carries a boxed warning for severe hypoglycaemia when used with insulin, and GLP-1 labelling records increased hypoglycaemia risk in combination with insulin or an insulin secretagogue. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Semaglutide
Labelled caution: two agents that slow gastric emptyingPramlintide labelling states that it slows gastric emptying, that it is not recommended for patients taking other drugs that alter gastrointestinal motility, and that concomitant oral medicines whose effect depends on a threshold concentration should be taken at least 1 hour before or 2 hours after injection. Semaglutide carries its own labelled statement that it delays gastric emptying and may affect the absorption of concomitantly administered oral medicines. This is therefore not an inference from shared mechanism - each product's own labelling describes the effect the other also produces. Pramlintide additionally carries a boxed warning for severe hypoglycaemia when used with insulin, and GLP-1 labelling records increased hypoglycaemia risk in combination with insulin or an insulin secretagogue. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Tirzepatide
Labelled caution: two agents that slow gastric emptyingPramlintide labelling states that it slows gastric emptying, that it is not recommended for patients taking other drugs that alter gastrointestinal motility, and that concomitant oral medicines whose effect depends on a threshold concentration should be taken at least 1 hour before or 2 hours after injection. Tirzepatide carries its own labelled statement that it delays gastric emptying and may affect the absorption of concomitantly administered oral medicines. This is therefore not an inference from shared mechanism - each product's own labelling describes the effect the other also produces. Pramlintide additionally carries a boxed warning for severe hypoglycaemia when used with insulin, and GLP-1 labelling records increased hypoglycaemia risk in combination with insulin or an insulin secretagogue. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Retatrutide
Labelled caution: two agents that slow gastric emptyingPramlintide labelling states that it slows gastric emptying, that it is not recommended for patients taking other drugs that alter gastrointestinal motility, and that concomitant oral medicines whose effect depends on a threshold concentration should be taken at least 1 hour before or 2 hours after injection. Retatrutide carries its own labelled statement that it delays gastric emptying and may affect the absorption of concomitantly administered oral medicines. This is therefore not an inference from shared mechanism - each product's own labelling describes the effect the other also produces. Pramlintide additionally carries a boxed warning for severe hypoglycaemia when used with insulin, and GLP-1 labelling records increased hypoglycaemia risk in combination with insulin or an insulin secretagogue. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Survodutide
Labelled caution: two agents that slow gastric emptyingPramlintide labelling states that it slows gastric emptying, that it is not recommended for patients taking other drugs that alter gastrointestinal motility, and that concomitant oral medicines whose effect depends on a threshold concentration should be taken at least 1 hour before or 2 hours after injection. Survodutide carries its own labelled statement that it delays gastric emptying and may affect the absorption of concomitantly administered oral medicines. This is therefore not an inference from shared mechanism - each product's own labelling describes the effect the other also produces. Pramlintide additionally carries a boxed warning for severe hypoglycaemia when used with insulin, and GLP-1 labelling records increased hypoglycaemia risk in combination with insulin or an insulin secretagogue. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Mazdutide
Labelled caution: two agents that slow gastric emptyingPramlintide labelling states that it slows gastric emptying, that it is not recommended for patients taking other drugs that alter gastrointestinal motility, and that concomitant oral medicines whose effect depends on a threshold concentration should be taken at least 1 hour before or 2 hours after injection. Mazdutide carries its own labelled statement that it delays gastric emptying and may affect the absorption of concomitantly administered oral medicines. This is therefore not an inference from shared mechanism - each product's own labelling describes the effect the other also produces. Pramlintide additionally carries a boxed warning for severe hypoglycaemia when used with insulin, and GLP-1 labelling records increased hypoglycaemia risk in combination with insulin or an insulin secretagogue. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Cagrilintide
Same receptor class: overlapping amylin-receptor activityPramlintide and cagrilintide are both amylin analogues acting on calcitonin/amylin receptor complexes, so they engage the same receptor population rather than adding a second mechanism. Both slow gastric emptying and promote satiation. Pramlintide is an approved product whose labelling carries a boxed warning for severe hypoglycaemia alongside insulin and states it is not recommended with other drugs that alter gastrointestinal motility; cagrilintide is investigational and has been studied in combination with semaglutide rather than with another amylin analogue. No study has characterised two amylin analogues given together. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Native GIP
Overlapping incretin-pathway activityPramlintide and Native GIP both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with MK-677
Opposing effects on glucose regulationMK-677 raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Pramlintide acts in the opposite direction on glycaemic control. Pramlintide is the sharper case: its labelling carries a boxed warning for severe hypoglycaemia in the insulin-treated setting, so an agent pushing glucose the other way makes the net effect harder to anticipate rather than conveniently cancelling out. MK-677 is also orally dosed, and the labelling for this metabolic class records delayed gastric emptying with potential effects on the absorption of concomitantly administered oral medicines. The combined effect on blood glucose is not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Tesamorelin
Opposing effects on glucose regulationTesamorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Pramlintide acts in the opposite direction on glycaemic control. Pramlintide is the sharper case: its labelling carries a boxed warning for severe hypoglycaemia in the insulin-treated setting, so an agent pushing glucose the other way makes the net effect harder to anticipate rather than conveniently cancelling out. The combined effect on blood glucose is not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with CJC-1295 with DAC
Opposing effects on glucose regulationCJC-1295 with DAC raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Pramlintide acts in the opposite direction on glycaemic control. Pramlintide is the sharper case: its labelling carries a boxed warning for severe hypoglycaemia in the insulin-treated setting, so an agent pushing glucose the other way makes the net effect harder to anticipate rather than conveniently cancelling out. The combined effect on blood glucose is not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Sermorelin
Opposing effects on glucose regulationSermorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Pramlintide acts in the opposite direction on glycaemic control. Pramlintide is the sharper case: its labelling carries a boxed warning for severe hypoglycaemia in the insulin-treated setting, so an agent pushing glucose the other way makes the net effect harder to anticipate rather than conveniently cancelling out. The combined effect on blood glucose is not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Ipamorelin
Opposing effects on glucose regulationIpamorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Pramlintide acts in the opposite direction on glycaemic control. Pramlintide is the sharper case: its labelling carries a boxed warning for severe hypoglycaemia in the insulin-treated setting, so an agent pushing glucose the other way makes the net effect harder to anticipate rather than conveniently cancelling out. The combined effect on blood glucose is not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with PT-141
Additive delay of gastric emptyingBremelanotide (PT-141) labelling states that it slows gastric emptying and may reduce the rate and extent of absorption of concomitantly administered oral medicines - patients are advised to avoid it alongside oral drugs that depend on threshold concentrations, and to avoid oral naltrexone products entirely because exposure is significantly decreased. Pramlintide carries the same labelled gastric-emptying caution, and pramlintide labelling goes further by stating it is not recommended with other drugs that alter gastrointestinal motility. Scheduling the two together therefore stacks two agents that independently delay gastric emptying, which matters most for any oral medicine taken in the same window. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Teduglutide
Opposing effects on intestinal absorptionTeduglutide is a GLP-2 analogue that increases villus height and crypt depth, enlarging absorptive surface area; its labelling records a potential for increased absorption of concomitant oral medicines and advises monitoring where a drug is titrated or has a narrow therapeutic index, since the oral drug may need its dose reduced. Pramlintide works in the opposite direction on the same variable - amylin-analogue labelling and pharmacology describe delayed gastric emptying, which slows the rate at which an oral medicine reaches the small intestine. One agent is enlarging the absorptive surface while the other is changing the timing of delivery to it, so the net effect on any co-administered oral medicine is not predictable from either alone. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Larazotide acetate
Delayed gastric emptying may alter delivery of an enteric-coated oralPramlintide labelling states that it delays gastric emptying and may affect the rate and extent of absorption of concomitantly administered oral medicines, and pramlintide labelling adds that it is not recommended for patients taking other drugs that alter gastrointestinal motility. Larazotide acetate is given as an enteric-coated oral capsule designed to release in the small intestine, acts locally on tight junctions there, and is minimally absorbed systemically - so what matters for it is where and when the capsule arrives, not a plasma concentration. Changing gastric emptying changes that delivery. Larazotide's own confirmatory phase 3 trial was stopped at interim analysis for futility, so there is no established effect size for it to lose in the first place; the interaction concern is about delivery, not about diminishing a proven benefit. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with CJC-1295 / Ipamorelin blend
Inherited from a component of this blendCJC-1295 / Ipamorelin blend contains Ipamorelin, and the catalogue holds a curated pair record between that component and Pramlintide: Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 with DAC / Ipamorelin blend
Inherited from a component of this blendCJC-1295 with DAC / Ipamorelin blend contains CJC-1295 with DAC and Ipamorelin, and the catalogue holds a curated pair record between those components and Pramlintide: CJC-1295 with DAC (opposing effects on glucose regulation); Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Sermorelin / Ipamorelin blend
Inherited from a component of this blendSermorelin / Ipamorelin blend contains Sermorelin and Ipamorelin, and the catalogue holds a curated pair record between those components and Pramlintide: Sermorelin (opposing effects on glucose regulation); Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Kyinsu
Inherited from a component of this blendKyinsu contains Semaglutide, and the catalogue holds a curated pair record between that component and Pramlintide: Semaglutide (labelled caution: two agents that slow gastric emptying). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CagriSema
Inherited from a component of this blendCagriSema contains Semaglutide and Cagrilintide, and the catalogue holds a curated pair record between those components and Pramlintide: Semaglutide (labelled caution: two agents that slow gastric emptying); Cagrilintide (same receptor class: overlapping amylin-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026HUMAN EVIDENCE
FDA-approved as adjunctive therapy with mealtime insulin in patients who have failed to achieve desired glucose control despite optimal insulin therapy. Trials showed modest HbA1c reduction with modest weight loss - an effect size well below the current incretin agents, which is part of why it is now infrequently used.
REPORTED EFFECTS
Boxed warning for severe hypoglycaemia, which occurs within three hours of injection and is most serious in type 1 diabetes; the mealtime insulin dose must be reduced by 50% when starting. Nausea is very common and dose-limiting. It is contraindicated in hypoglycaemia unawareness and in confirmed gastroparesis.
RESEARCH LIMITATIONS
This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.
CURATED SOURCES · 1